Sarah de Crescenzo
Xconomy
San Diego, CA, United States
Contact Sarah
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Sarah:
Xconomy: AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial
A formulation of AbbVie’s blockbuster wrinkle treatment, acquired through its buyout of Allergan, has failed a mid-stage trial as a potential fix for → Read More
Xconomy: Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies
Drugs designed to precisely target cancers with specific genetic signatures have changed the course of disease for many patients. But for the majority, → Read More
Xconomy: Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early
The ability to detect early signs of cancer in a patient’s blood could improve prognoses by helping doctors treat the disease before symptoms arise. → Read More
Xconomy: Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout
Acadia Pharmaceuticals has acquired Texas biotech CerSci Therapeutics, a privately held company with a clinical-stage molecule under evaluation as a → Read More
Xconomy: FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines
The FDA has authorized the use of plasma from people who have recovered from infection by the novel coronavirus as a treatment for hospitalized COVID-19 → Read More
Xconomy: Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More
While business is historically slow in August, this month seems to be bucking the trend, just like so many other unexpected developments in 2020. Perhaps → Read More
Xconomy: Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts
Two biotechs this week topped the $100 million mark in their respective initial public offerings, both of which were able to offer more shares than → Read More
Xconomy: FDA Rejects BioMarin Hemophilia Gene Therapy, Asks for More Data
A gene therapy designed to treat the severest cases of the most common type of hemophilia has been rejected by the FDA, which wants more data on the → Read More
Xconomy: Patient Death in Poseida Prostate Cancer Study Prompts Clinical Hold
A Phase 1 trial testing a Poseida Therapeutics cell therapy in men with prostate cancer is on hold after a patient enrolled in the study died of liver → Read More
Xconomy: Genentech Gets FDA OK for Injectable Rare Neuroimmune Disease Drug
A drug that can be administered at home to treat a rare central nervous system disorder that damages the optic nerves and spinal cord now has FDA → Read More
Xconomy: Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor
Cancer drug developer Tango Therapeutics is adding $175 million more to its coffers in cash and equity, funds the company says will help it get its lead → Read More
Xconomy: Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy
Bristol Myers Squibb is paying nearly half a billion dollars in up front and near-term payments to license an early-stage immunotherapy developed by → Read More
Xconomy: Advisory Body Backs MesoBlast Therapy for Transplant Complication
An FDA advisory committee Thursday voted 9-1 to recommend that the agency approve a stem cell therapy developed by MesoBlast as a treatment for acute → Read More
Xconomy: Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia
Two California biotechs have teamed up with LianBio, a new company launched earlier this week by hedge fund Perceptive Advisors, as part of deals that → Read More
Xconomy: Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup
Ligand Pharmaceuticals plans to acquire recombinant protein therapeutics maker Pfenex for $438 million, the companies announced Monday. The larger company → Read More
Xconomy: Roche Gut Disease Drug Produces Mixed Results in Late-Stage Trials
Results from four studies within a major Roche-run clinical trials program of an investigational gut disease drug have muddled the antibody’s path forward → Read More
Xconomy: FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
The FDA on Friday approved a new spinal muscular atrophy drug that patients can take at home. Risdiplam (Evrysdi) is a liquid medicine intended for daily → Read More
Xconomy: Bio Roundup: A Telehealth Combo, FDA's BCMA OK, Biogen's Bet & More
The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. Big Pharma companies are focusing on vaccine development → Read More
Xconomy: GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod
Patients with advanced multiple myeloma have a new treatment option with the FDA’s approval of a GlaxoSmithKline drug that targets B-cell maturation → Read More
Xconomy: G1 Vets Launch Arc Therapeutics to Take on New Cancer Target
Three early employees of G1 Therapeutics have launched a new oncology-focused company and raised $6 million to move a preclinical program licensed from → Read More